SelectMDx for Prostate Cancer
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate specific antigen (PSA) is considered the best screening test for the early detection of prostate cancer and, if elevated, prostate biopsy is typically performed to confirm the presence of cancer and determine the pathologic grade. However, an elevated PSA result could be caused by factors other than cancer, including infection, inflammation or benign prostatic hyperplasia (BPH). As 18% of men experience complications after prostate biopsy and up to 3% might require hospitalization as a result of the procedure, it would be useful to further stratify patients as to their cancer risk and therefore the need for biopsy.
SelectMDx is a noninvasive laboratory test performed on a urine sample, which measures mRNA levels of DLX1 and HOXC6. This test helps to stratify patients with elevated PSA levels as an aid in deciding to proceed with prostate biopsy or to avoid a biopsy and continue routine screening. This test has a 95% negative predictive value (NPV) for clinically significant prostate cancer when used in men with PSA levels of 4-10ng/ml, and potentially enables the patient to avoid an invasive diagnostic procedures and potential complications when the results are ‘low risk’.
- To determine whether patient is at higher or lower risk for prostate cancer
- To determine a biopsy is required
Normal:
Low levels of DLX1 and HOXC6 are not associated with an increased risk of prostate cancer. Individuals with a low risk score on this test may be able to avoid a biopsy
Abnormal:
Higher levels of DLX1 and HOXC6 are associated with an increased risk of prostate cancer. Individuals with a high-risk score on SelectMDx may need a biopsy
Normal: Low levels of DLX1 and HOXC6, biopsy should be avoided
Liquid biopsy or urine collection.
Stability
- Ambient; 3-5 days
- Refrigerated; 7 days
- J Urol. 2019;202: 256-63. [PMID: 31026217]
- World J Oncol. 2019; 10: 63–89. [PMID: 31068988]
- J Urol. 2018;200: 1221-26. [PMID: 30012363]
- Eur Urol. 2016;70: 740-8. [PMID: 27108162]
- Acta Med Indones 2016:48:228-238. [PMID: 27840359]
- Clin Cancer Res. 2015;21: 3061-70. [PMID: 25788493]